Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
114 hedge funds and large institutions have $958M invested in Trillium Therapeutics Inc. in 2020 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 37 increasing their positions, 25 reducing their positions, and 12 closing their positions.
250% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 12
110% more capital invested
Capital invested by funds: $455M → $958M (+$503M)
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
90% more call options, than puts
Call options by funds: $14.1M | Put options by funds: $7.39M
48% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 25
36% more funds holding
Funds holding: 84 → 114 (+30)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$24.9M |
| 2 |
RI
RTW Investments
New York
|
+$21.5M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$17.4M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$12.6M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$8.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$33M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.31M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.14M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$3.23M |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$3.05M |
TRIL Hedge Fund Activity: Q3 2020 in Review
114 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q3 2020, worth a combined $958M — up 110% from $455M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new TRIL positions and 12 closed out — a net gain of 30 holders — while 37 added to existing stakes and 25 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $24.9M. The largest seller was Boxer Capital, exiting entirely with an estimated $33M sold.
- 114 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q3 2020, up from 84 in Q2 2020.
- Funds reported $958M of Trillium Therapeutics Inc. stock for Q3 2020, up 110% quarter-over-quarter.
- 42 funds opened new Trillium Therapeutics Inc. positions in Q3 2020 and 12 closed out, a net change of +30 holders.
- The largest Trillium Therapeutics Inc. buyer in Q3 2020 was Cormorant Asset Management, an estimated $24.9M added.
- The largest Trillium Therapeutics Inc. seller in Q3 2020 was Boxer Capital, an estimated $33M sold.
Based on aggregated 13F filings for Q3 2020.